Printer Friendly

Aethlon Medical to Present at Orange County Life Sciences Conference on February 7th at 12pm PST.

SAN DIEGO -- Aethlon Medical, Inc., (OTCBB:AEMD) a pioneer in developing therapeutic devices for infectious disease, announced today that its Chairman and CEO, James A. Joyce will present at the Friedland Capital Life Sciences Conference at 12pm PST, this Wednesday the 7th of February. In addition to providing a corporate update, Mr. Joyce will discuss new collaborations with researchers at The Centers for Disease Control (CDC), The United States Army Medical Research Institute of Infectious Diseases (USAMRIID), and the Government of India's National Institute of Virology (NIV).

The event will be held at the Hilton Hotel in Irvine, California. To attend the presentation, please contact Friedland Capital at 212-757-9454.

About Aethlon Medical

Aethlon Medical has developed a first-in-class medical device to treat infectious disease. The device, known as the Hemopurifier([R]), is a broad-spectrum treatment countermeasure against drug and vaccine resistant bioweapons, naturally evolving pandemic threats, and chronic infectious disease targets including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Global researcher, Frost & Sullivan, awarded Aethlon the 2006 Technology Innovation Award for its advances in the field of biodefense. The company has also initiated research on a second generation Hemopurifier([R]) that targets the capture of growth factors inherent in the spread of Cancer. More information on Aethlon Medical and the Hemopurifier(TM) technology can be found at

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 5, 2007
Previous Article:Air-Trak Announces Location Tracking Solution for Microsoft Windows-Based Laptops and Windows Mobile 5.0 Devices.
Next Article:AstraZeneca Licenses Regeneron's VelocImmune(R) Technology for Discovering Human Monoclonal Antibodies.

Related Articles
General Environmental Health Educational Program.
Aethlon Medical to Present at 2006 Global Equities Conference.
Aethlon Medical Initiates Dengue Fever Studies with Government of India Researchers.
Aethlon Medical Discloses CEO Interview at 12:15pm EST Tomorrow.
Aethlon Medical Releases Shareholder Letter.
Aethlon Medical Releases Dengue Treatment Data.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters